Sarepta appoints Deirdre Connelly to board, increases board size to 9

Sarepta Therapeutics, Inc.

Deirdre Connelly appointed as Class I director effective Sept. 12, 2024, term through 2026 annual meeting.
Initial equity grant of $712,500 in value, split equally between RSUs and stock options.
Equity vests in three equal annual installments starting Sept. 12, 2025; annual cash retainer $60,000.
Board amended bylaws to increase maximum director limit from 8 to 9, effective immediately.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Deirdre Connelly

Director

SRPT · Sarepta Therapeutics, Inc.

Effective: 2024-09-12
Filed: September 16, 2024, 7:59 PM ET

On September 12, 2024, the board of directors (the “ Board ”) of Sarepta Therapeutics, Inc. (the “ Company ”) appointed Deirdre Connelly as a director of the Company, effective immediately, to serve as a member of Class I until the 2026 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Deirdre Connelly was appointed as Director at Sarepta Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On September 12, 2024, the board of directors (the “ Board ”) of Sarepta Therapeutics, Inc. (the “ Company ”) appointed Deirdre Connelly as a director of the Company, effective immediately, to serve as a member of Class I until the 2026 annual meeting of stockholders.

View on SEC.gov

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-106619

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.